MX369520B - Uso de una combinación farmacéutica para el tratamiento de fibromas uterinos. - Google Patents

Uso de una combinación farmacéutica para el tratamiento de fibromas uterinos.

Info

Publication number
MX369520B
MX369520B MX2014011487A MX2014011487A MX369520B MX 369520 B MX369520 B MX 369520B MX 2014011487 A MX2014011487 A MX 2014011487A MX 2014011487 A MX2014011487 A MX 2014011487A MX 369520 B MX369520 B MX 369520B
Authority
MX
Mexico
Prior art keywords
gynecological diseases
treating gynecological
pharmaceutical composition
receptor modulator
progesterone receptor
Prior art date
Application number
MX2014011487A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011487A (es
Inventor
Gotteland Jean-Pierre
Boujac Valérie
Loumaye Ernest
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of MX2014011487A publication Critical patent/MX2014011487A/es
Publication of MX369520B publication Critical patent/MX369520B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2014011487A 2012-03-23 2013-03-22 Uso de una combinación farmacéutica para el tratamiento de fibromas uterinos. MX369520B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
EP12160956.4A EP2641602A1 (en) 2012-03-23 2012-03-23 Method for treating gynecological diseases
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Publications (2)

Publication Number Publication Date
MX2014011487A MX2014011487A (es) 2015-01-12
MX369520B true MX369520B (es) 2019-11-11

Family

ID=45976689

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011487A MX369520B (es) 2012-03-23 2013-03-22 Uso de una combinación farmacéutica para el tratamiento de fibromas uterinos.

Country Status (18)

Country Link
US (1) US10441534B2 (enExample)
EP (3) EP2641602A1 (enExample)
JP (2) JP2015514700A (enExample)
KR (1) KR20140138824A (enExample)
CN (1) CN104203246A (enExample)
AU (1) AU2013236960B2 (enExample)
CA (1) CA2864073A1 (enExample)
CO (1) CO7111317A2 (enExample)
EA (1) EA031488B1 (enExample)
GE (1) GEP201706696B (enExample)
HK (1) HK1199827A1 (enExample)
MX (1) MX369520B (enExample)
MY (1) MY172530A (enExample)
NZ (1) NZ630011A (enExample)
SG (1) SG11201404921QA (enExample)
TW (2) TW201832767A (enExample)
WO (1) WO2013140372A1 (enExample)
ZA (1) ZA201407575B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
EP0180264A1 (en) 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2004217988C1 (en) 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
SI2148681T1 (sl) * 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
ES2648640T3 (es) * 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos

Also Published As

Publication number Publication date
EA201491614A1 (ru) 2015-01-30
WO2013140372A1 (en) 2013-09-26
TW201400121A (zh) 2014-01-01
TW201832767A (zh) 2018-09-16
AU2013236960A1 (en) 2014-09-25
NZ630011A (en) 2016-12-23
EP2827873A1 (en) 2015-01-28
SG11201404921QA (en) 2014-10-30
CA2864073A1 (en) 2013-09-26
EP3363500A1 (en) 2018-08-22
MY172530A (en) 2019-11-29
JP2015514700A (ja) 2015-05-21
US20150038476A1 (en) 2015-02-05
US10441534B2 (en) 2019-10-15
CN104203246A (zh) 2014-12-10
HK1199827A1 (en) 2015-07-24
GEP201706696B (en) 2017-07-10
JP2018109025A (ja) 2018-07-12
ZA201407575B (en) 2015-12-23
CO7111317A2 (es) 2014-11-10
EA031488B1 (ru) 2019-01-31
MX2014011487A (es) 2015-01-12
AU2013236960B2 (en) 2017-11-23
KR20140138824A (ko) 2014-12-04
EP2641602A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
PH12014502516B1 (en) Formulations and methods for vaginal delivery of antiprogestins
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
JOP20130236B1 (ar) تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188139A (en) Sodium channel modulators for the treatment of pain
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY172530A (en) Method for treating gynecological diseases
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12015501596B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
PH12012501389A1 (en) Hedgehog inhibitors
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
MX372644B (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
CA2864049A1 (en) Use of beta-nerve growth factor for inducing ovulation in mammals
UA75384U (ru) Способ профилактики осложнений в послеродовом периоде у женщин с фиброзно-кистозной болезнью молочных желез

Legal Events

Date Code Title Description
FG Grant or registration